Skip to main content
Premium Trial:

Request an Annual Quote

InterWest Health Providing its Members Access to Genetic Technologies' Breast Cancer Test

NEW YORK (GenomeWeb News) – Genetic Technologies today announced an agreement with InterWest Health to provide the preferred provider organization's members access to GTG's BrevaGen breast cancer diagnostic test.

The deal is the eighth that Melbourne, Australia-based GTG has reached with a US PPO. The deal was forged between its wholly owned subsidiary Phenogen Sciences and InterWest, a regional provider network based in Missoula, Mont. servicing seven states in the northwest US. InterWest's network includes more than 15,000 health care providers, GTG said.

Before today's announcement, GTG in June inked a similar agreement with FedMed. GTG said that more than 102 million lives now have access to BrevaGen as an in-network benefit.